Login to Your Account



Clinic Roundup


Monday, March 12, 2012

• Moberg Derma AB, of Stockholm, Sweden, said the German-Federal Institute for Drugs and Medical Devices granted approval for a Phase I trial of Limtop, a product in development for actinic keratosis, genital warts and basal cell carcinoma. The drug is a new formulation of an immunomodulatory compound that has shown improved delivery to skin tissue in preclinical studies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription